Overview

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Status:
Not yet recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Treatments:

Bevacizumab